927 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
Rank Status Study
21 Recruiting G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
Condition: Small Cell Lung Cancer
Interventions: Drug: G1T28 + carboplatin/ etoposide;   Drug: Placebo + carboplatin/ etoposide
22 Recruiting Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Crizotinib
23 Not yet recruiting A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Glioblastoma Multiforme;   Melanoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Sarcoma;   Renal Cell Carcinoma
Intervention: Drug: DSP-7888 Dosing Emulsion
24 Not yet recruiting Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Small Cell Lung Carcinoma;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: 18F-Fluoromisonidazole;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Procedure: Positron Emission Tomography
25 Not yet recruiting EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: EGFR Activating Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: EGFR Inhibitor AZD9291;   Other: Laboratory Biomarker Analysis;   Biological: Necitumumab;   Other: Pharmacological Study
26 Recruiting Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis
Conditions: Lung Cancer;   Non-small Cell Lung Cancer;   Small Cell Lung Cancer;   Pleural Mesothelioma;   Thymoma
Interventions: Drug: Nintedanib;   Drug: Prednisone;   Other: Placebo
27 Not yet recruiting Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
Conditions: Head and Neck Squamous Cell Carcinoma;   Metastatic Pancreatic Adenocarcinoma;   Non-Resectable Cholangiocarcinoma;   Pancreatic Adenocarcinoma;   Recurrent Gallbladder Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Gallbladder Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Gallbladder Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Unresectable Gallbladder Carcinoma;   Unresectable Pancreatic Cancer
Interventions: Drug: Cisplatin;   Drug: Docetaxel;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel Albumin-Stabilized Nanoparticle Formulation;   Other: Pharmacological Study;   Biological: Recombinant EphB4-HSA Fusion Protein
28 Not yet recruiting Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: CDX-1401;   Drug: MPDL3280A
29 Not yet recruiting A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: ASP2215;   Drug: Erlotinib
30 Not yet recruiting A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Radiation: Response-driven Adaptive Radiation Therapy;   Drug: Carboplatin;   Drug: Paclitaxel;   Device: FDG-PET;   Device: V/Q SPECT
31 Recruiting Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: pembrolizumab;   Radiation: Stereotactic Body Radiation Therapy
32 Recruiting Afatinib Genomic Landscape
Conditions: Carcinoma, Non-Small-Cell Lung;   Non-Small Cell Lung Cancer;   Non-small Lung Cancer
Intervention:
33 Recruiting Comparative Study of the Hypoxia Measured in FAZA and F-miso TEP/CT Scan in Patients With Non-small Cell Lung Cancer at the Time of Diagnosis : Correlation With Immunohistochemistry
Condition: Non-small Cell Lung Cancer
Interventions: Device: Miso PET scan;   Device: FAZA PET scan
34 Recruiting RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens
Conditions: Small Cell Lung Carcinoma;   Carcinoma, Non-Small-Cell Lung;   Neuroendocrine Tumors
Interventions: Drug: RRx-001;   Drug: Cisplatin/carboplatin plus albumin (nab-paclitaxel or Abraxane);   Drug: cisplatin/carboplatin plus etoposide
35 Recruiting Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC
Condition: Non-small Cell Lung Cancer
Interventions: Procedure: Surgery;   Radiation: SABR
36 Not yet recruiting Maintaining ERBB Blockade in EGFR-mutated Lung Cancer
Condition: Non-small-cell Lung Cancer With Somatic EGFR Mutations
Interventions: Drug: Afatinib;   Drug: Pemetrexed
37 Recruiting Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer
Conditions: Carcinoma, Non-Small -Cell Lung;   Ovarian Neoplasms;   Small Cell Lung Carcinoma;   Uterine Cervical Neoplasms;   Carcinoma, Neuroendocrine
Interventions: Drug: Topotecan;   Drug: VX-970
38 Recruiting Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Atezolizumab (MPDL3280A);   Other: Best Supportive Care (BSC)
39 Not yet recruiting Study Evaluating the Efficacy, Safety and Pharmacokinetics in Patient With T790M-positive Non-small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Intervention: Drug: HM61713 tablet
40 Not yet recruiting Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years